Cancer Therapies
Total Trials
2
As Lead Sponsor
0
As Collaborator
Total Enrollment
62
NCT05649228
Thermosensitivity of a Topical Palmitated Formulation of Capsaicin
Phase: Early Phase 1
Role: Collaborator
Start: Dec 13, 2022
Completion: Jan 11, 2024
NCT05618301
Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)
Phase: Phase 1
Start: Jul 7, 2023
Completion: Jun 24, 2025
Loading map...